Wall Street analysts forecast that Edwards Lifesciences (EW) will report quarterly earnings of $0.62 per share in its upcoming release, pointing to a year-over-year decline of 11.4%. It is anticipated that revenues will amount to $1.49 billion, exhibiting a decrease of 8.9% compared to the year-ago quarter.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this ...

核心财务预测 - 华尔街分析师预计Edwards Lifesciences季度每股收益为0.60美元，同比下降9.1% [1] - 预计季度收入为14亿美元，同比下降12.2% [1] - 过去30天内共识EPS预测保持未变，反映分析师对初始预测的集体重新评估 [1] 产品组销售预测 - 经导管二尖瓣和三尖瓣治疗产品组净销售额预计达1.1382亿美元，同比增长56.1% [4] - 外科结构性心脏病产品组净销售额预计达2.5451亿美元，同比下降4.4% [4] - 经导管主动脉瓣置换产品组净销售额预计达10.3亿美元，同比增长2.2% [5] 区域销售预测 - 欧洲地区净销售额预计达3.5701亿美元，同比下降2.9% [5] - 美国以外地区净销售额预计达5.7377亿美元，同比下降12.7% [6] - 美国本土净销售额预计达8.4903亿美元，同比下降9.8% [6] - 日本市场净销售额预计达9640万美元，同比下降13% [6] - 世界其他地区净销售额预计达1.2036亿美元，同比大幅下降32.7% [7] 市场表现 - 公司股价过去一个月上涨0.8%，同期标普500指数下跌6.9% [7] - 公司当前Zacks评级为3级(持有)，预计将跟随整体市场走势 [7]